Get started
Author

Zaina Sangale

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
2016 · Melinda L. Telli, Kirsten M. Timms, et al. · Clinical Cancer Research · 1,152
Association of BRCA1/2defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes
2014 · Kirsten M Timms, Victor Abkevich, et al. · Breast Cancer Research · 427
PDF
Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy
2014 · Jay T. Bishoff, Stephen J. Freedland, et al. · The Journal of Urology · 191
Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy
2013 · Stephen J. Freedland, Leah Gerber, et al. · International Journal of Radiation Oncology*Biology*Physics · 183
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer
2017 · Melinda L. Telli, Jessica Hellyer, et al. · Breast Cancer Research and Treatment · 120
Validation of a Proliferation-Based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma
2013 · Ignacio I. Wistuba, Carmen Behrens, et al. · Clinical Cancer Research · 106
Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
2013 · on behalf of the Transatlantic Prostate Group, J Cuzick, et al. · British Journal of Cancer · 105
PDF
PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer
2014 · Prabhakar Mithal, Emma Allott, et al. · International Journal of Urology · 98
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
2015 · Virginia G. Kaklamani, Jacqueline S. Jeruss, et al. · Breast Cancer Research and Treatment · 77
A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma
2017 · Todd M. Morgan, Rohit Mehra, et al. · European Urology · 72
A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors
2010 · Zaina Sangale, Cynthia Prass, et al. · Applied immunohistochemistry & molecular morphology · 68
PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival
2013 · Chloe E. Atreya, Zaina Sangale, et al. · Cancer Medicine · 52
PDF
Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer
2018 · Daniel J. Canter, Julia Reid, et al. · European Urology · 30
PDF
Prediction of distant recurrence in resected stage I and II lung adenocarcinoma
2016 · Beatrice Aramini, Christian Casali, et al. · Lung Cancer · 27
Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy
2018 · Priscilla Léon, Geraldine Cancel-Tassin, et al. · World Journal of Urology · 23
Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
2016 · Michael O. Koch, Jane S. Cho, et al. · Cancer Biomarkers · 19
PDF
Cell cycle progression score predicts metastatic progression of clear cell renal cell carcinoma after resection
2015 · Eric J. Askeland, Vincent A. Chehval, et al. · Cancer Biomarkers · 19
PDF
3-biomarker HRD score versus individual biomarker (LOH, TAI, LST) scores in platinum treated serous ovarian cancer (SOC)
2016 · J. Lanchbury, K. Timms, et al. · Annals of Oncology · 8
PDF
214 Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancer
2014 · P. Haluska, K.M. Timms, et al. · European Journal of Cancer · 7
Abstract P5-06-04: The PARP inhibitor niraparib demonstrated activity in patient-derived triple-negative breast cancer xenograft models with high homologous recombination deficiency (HRD) score
2015 · Yan Wang, Stefano Cairo, et al. · Cancer Research · 6
Abstract P6-05-10: Association between BRCA1/2 status and DNA-based assays for homologous recombination deficiency in breast cancer
2013 · KM Timms, V Abkevich, et al. · Cancer Research · 6
Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.
2015 · Melinda L. Telli, Kirsten Timms, et al. · Journal of Clinical Oncology · 5
Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology.
2013 · Thorsten Schlomm, Zaina Sangale, et al. · Journal of Clinical Oncology · 5
The molecular landscape of genome instability in prostate cancer (PC)
2016 · K. Timms, J. Cuzick, et al. · Annals of Oncology · 4
PDF
Cell Cycle Progression Score, but Not Phosphatase and Tensin Homolog Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-risk Prostate Cancer in Men Treated With and Without Salvage Radiotherapy
2022 · Bruce J. Trock, Yuezhou Jing, et al. · The Journal of Urology · 3
Works count: 58
Citation count: 2,826
H-index: 17
I10-index: 17
Year
Topic
Type